Competitors in the diabetes market are working to meet consumer demand for more digitally integrated and interconnected diabetes management solutions, and collaborations among the various participants represent the new norm in this industry. In this ICYMI, Big pharma Eli Lilly partners with medtech to shift its diabetes focus from molecules to outcomes.
In this week’s edition of “In MedTech History,” we highlight recent developments in the brave new world of automated diabetes devices, including Tandem Diabetes Care’s US launch of its t:slim X2 Insulin Pump with predictive Basal-IQ Technology. Advancements such as these couldn’t be coming at a more opportune time: Diabetes is now the most costly chronic illness in the US, according to the American Diabetes Association.
The evolution in device-based diabetes management began more than 50 years ago. Today, fueled by US healthcare costs approaching $330 billion and exponential global growth in incidence and prevalence, device technologies—powered by the promise of data and analytics—are helping to simplify the lives of diabetic patients and at the same time combat the rise in the cost of care. In this edition, we take a look at DexCom’s acquisition of TypeZero Technologies.
Meet Jason McKeown, co-founder and CEO of Neurovalens, an independent “careable technology” company whose Modius Health platform is using neuroscience with the goal of solving the mega-problems of obesity, diabetes, epilepsy, migraine, arthritis, anxiety, depression, and if that's not enough, even long-term space travel. In this candid interview onsite in Dublin with our Associate Analyst Kayleen Brown, CEO Jason McKeown talks about his inspiration and early experiences in co-founding the company, his current priorities, and the surprises and lessons he has learned so far in his start-up journey.